700 Collip Circle
London, ON N6G 4X8
Full Time Employees:
|Ms. Alison D. Silva MA, MS||CEO, Pres & Director||68.76k||N/A||N/A|
|Mr. Eugene Francis Kelly||Chief Financial Officer||N/A||N/A||N/A|
|Ms. Debi Sanderson MBA||Director of Resourcing & Operations||N/A||N/A||N/A|
|Dr. Richard T. Ho M.D., Ph.D.||Chief Scientific Officer||N/A||N/A||54|
|Mr. Paul Papi||VP of Investor Relations||N/A||N/A||N/A|
Critical Outcome Technologies Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. Its lead compound is COTI-2, a novel small molecule activator of misfolded mutant p53 proteins, which is in Phase I clinical trial for the treatment of gynecologic cancers, as well as head and neck squamous cell carcinoma. The company also develops COTI-219, a novel oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS function; drug candidates for the treatment of acute myelogenous leukemia, SOX9, MRSA, multiple sclerosis, and Alzheimers disease; and HIV integrase inhibitors. Critical Outcome Technologies Inc. was founded in 1999 and is based in London, Canada.
Critical Outcome Technologies Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.